We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Chinese company has been approved by the State Food and Drug Administration (SFDA) to produce the anti-flu drug, Tamiflu, sources with the SFDA said Tuesday.
Israeli drug company Can-Fite BioPharma has completed preclinical trials testing the metabolism and excretion of its lead drug CF101 for the treatment of rheumatoid arthritis (RA).
New York-based Pfizer has completed the acquisition of worldwide rights to the new drug candidate fesoterodine from German company Schwarz Pharma AG, the company announced.
Swiss drugmaker Novartis has announced the expansion of its late-stage vaccines pipeline through an agreement to acquire marketing and distribution rights for Intercell's IC51, a vaccine in Phase III clinical trials for the prevention of infections from the Japanese encephalitis virus.
Idian drugmaker Ranbaxy Pharmaceuticals has received approval from the U.S. FDA to manufacture and market doxycycline tablets at strengths of 50 mg, 75 mg and 100 mg in the U.S. market.
Pharmaceutical giant Pfizer Inc (PFE.NYS) Tuesday announced that it had completed the acquisition of the worldwide rights of Schwarz Pharma AG's (SRZ) new drug candidate, fesoterodine, for the treatment of an overactive bladder.
Aspreva Pharmaceuticals Corporation, an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, today announced that William Hunter, MD, MSc has been appointed to the Company's Board of Directors.
Aida Pharmaceuticals, Inc., one of mainland China's leading pharmaceutical companies, today announced that the Company has expanded its drug development pipeline with three new drugs.
Family-controlled and very secretive, German drugs company Merck seems to embody the values of the country's Mittelstand, the slew of small and medium-sized companies that are still the bedrock of the economy.
Swiss pharmaceutical giant Novartis AG Tuesday announced that it was acquiring the marketing and distribution rights for IC51, a new vaccine in phase three trials, from Austria's Intercell AG.